- AstraZeneca’s COVID-19 vaccine found 74% effective against symptomatic infections in its large US trial results
- Efficacy increased to 83.5% in participants 65 years of age or older
- There were no cases of severe or severe COVID-19 and no deaths among those who received the vaccine, compared to 8 cases and 2 deaths in the placebo group
- No cases of a rare but serious blood clotting side effect called thrombosis were observed with AstraZeneca vaccine-associated thrombocytopenia.
- The company plans to file for full FDA approval this fall after multiple setbacks delayed its plans to file for emergency use authorization in spring 2021.
- AstraZeneca vaccine is unlikely to be widely used in the US, with 184.3 million fully vaccinated and over 77% of adults with at least one dose
AstraZeneca plc’s COVID-19 vaccine is highly effective against infections – particularly in older adults, according to new data from the company’s US clinical trials.
The vaccine, developed with researchers from the University of Oxford, was found to be 74 percent effective against symptomatic COVID infections.
Efficacy increased to about 84 percent in participants 65 years of age and older.
This makes AstraZeneca’s vaccine less protective against infection than Pfizer-BioNtech and Moderna vaccines, 88.8 percent and 96.3 percent, respectively, but 70 percent more protective than Johnson & Johnson’s vaccine.
It comes as AstraZeneca plans to seek full approval of the shot with the US Food and Drug Administration (FDA) this fall after a series of setbacks prompted the firm to rapidly apply for emergency use authorization (EUA) in the spring. delayed in
AstraZeneca’s COVID-19 vaccine was found to be 74% effective against symptomatic infections in the results of its large US trial, with efficacy increasing to 83.5% in participants 65 years of age or older. Image: AstraZeneca’s vaccine boxes, June 2021
There were no cases of severe or severe COVID-19 and no deaths among those who received the vaccine, compared with 8 cases and 2 deaths in the placebo group (above).
AstraZeneca’s COVID-19 vaccination is known as a viral vector vaccine, the same type of shot as the Johnson & Johnson vaccine.
Viral vector vaccines combine genetic material from SARS-CoV-2 – the virus that causes COVID – with genes from the adenovirus, which causes the common cold.
Part taken from SARS-CoV-2 codes for the spike protein, which the coronavirus uses to enter and infect cells so that the body can be trained to recognize the virus and induce an immune response when infected .
for the trial, the results of which have been published The New England Journal of Medicine On Wednesday, the team looked at 32,000 volunteers in the US, Chile and Peru.
Two-thirds of the volunteers received two shots of the vaccine spaced four weeks apart, while the remaining one-third received two placebo shots.
AstraZeneca’s COVID vaccine is more protective against infection than J&K – but less than Pfizer and Moderna
AstraZeneca’s efficacy against infection: 74%
Efficacy of Pfizer-BioNTech against infection: 88.8%
Moderna’s efficacy against infection: 96.3%
Johnson & Johnson’s efficacy against infection: 70%
There were no cases of severe or severe symptomatic COVID-19 in participants who received the vaccine, compared with eight such cases in volunteers who received placebo.
Additionally, there were two COVID deaths in the placebo group, but none of those receiving the vaccine.
Researchers determined that the COVID-19 vaccine demonstrated 74 percent efficacy in preventing symptomatic disease and 83.5 percent efficacy in people 65 years of age and older.
“I was pleasantly surprised,” Dr Anna Durbin, a vaccine researcher at Johns Hopkins University and one of the study’s investigators, told Reuters of the overall result.
‘It was also highly protective against serious illness and hospitalization.’
The most common side effects reported by vaccine recipients were general pain, headache, injection site pain, and fatigue.
There were no cases of thrombocytopenia with a rare but serious blood clotting side effect called thrombosis that has been linked to the AstraZeneca vaccine.
The company originally planned to file for the EUA in the US in the spring of 2021, but has faced several setbacks since last year.
In September 2020, AstraZeneca’a. US branch of Vaccine trial was stopped after A British participant was taken to hospital after a severe reaction that caused spinal cord swelling.
The company then did not provide trial safety data to the FDA for a month, further delaying the resumption of the study.
When AstraZeneca released the results of an interim analysis of its clinical trial showing 79 percent efficacy in March 2021, US health officials claimed the figure was based on ‘outdated information’.
AstraZeneca vaccine is unlikely to be widely used in the US, with 184.3 million fully vaccinated and over 77% of adults with at least one dose
The British drugmaker revised the figure a few days later to 76 percent.
In April, the firm said it was struggling to pull together the data needed to apply for emergency use authorization in the US.
AstraZeneca said in late July that it planned to file for full approval with the FDA rather than seek emergency use authorization.
CEO Pascal Soriot said at a media briefing at the time that he hoped the vaccine could still play a role in the US, even though the process was taking longer than expected.
The company is exploring booster doses for people who have already been vaccinated with its own shot or two doses of mRNA-based vaccines from Pfizer/BioNTech or Moderna.
Durbin told Reuters he does not expect much of the vaccine to be used in the US, noting that most adults have already received one and that children may only be allowed to get the Pfizer shot.
But, she said that securing FDA approval “gives them …